Mount Sinai increasingly is turning to embolization to help remove skull base tumors such as meningiomas more completely, selectively, and safely. Using a strategy devised by its biomedical incubator, Mount Sinai BioDesign, surgeons can now assess and quantify the extent of embolization through an analysis of an additional MRI sequence following embolization and preceding surgical resection.
